Beckley Psytech

Biotech · Oxford, GB

Biotech developing psychedelic compounds into licensed medicines.

Founders

Cosmo Feilding Mellen (United Kingdom · ♂) — Son of psychedelic-research pioneer Amanda Feilding, he co-founded Beckley Psytech in 2019 as CEO to translate the Beckley Foundation's decades of psychedelic science into licensed medicines.
Amanda Feilding (United Kingdom · ♀) — A leading authority on psychedelic science through her Beckley Foundation (founded 1998), she co-founded Beckley Psytech in 2019 to commercialize that research into psychiatric drug treatments.

Date	Round	Amount
Aug 2021	Series B UK psychedelics biotech Beckley Psytech raised a USD 80M Series B led by Integrated.	$80M
Dec 2020	Series A UK psychedelic medicine developer Beckley Psytech raised GBP14M (about EUR15.5M) in an equity round with new investors Noetic Psychedelic Fund and Bail Capital.	$17.4M

Tap an investor to see what else they have backed.

Data is community-curated and may be incomplete.